Jaros

Tirzepatide is a new-generation medication for weight loss, treatment of obesity, and treatment of diabetes mellitus.
It is a dual receptor agonist (GIP and GLP-1), unlike Ozempic, which is an agonist of only GLP-1.
The drug was officially approved by the FDA (USA) in 2022 for the treatment of obesity and type 2 diabetes. In Europe, it was approved in 2023.

A double strike against obesity:

Activation of GLP-1 receptors
suppresses glucagon secretion, which raises blood sugar levels,
slows gastric emptying, which leads to a slower entry of glucose into the bloodstream,
affects the satiety centers in the hypothalamus, reducing appetite and increasing the feeling of fullness.
This promotes weight loss.

Activation of GIP receptors (the key difference from GLP-1–only analogues):
enhances the effects of GLP-1 and improves the metabolism of fat cells (adipocytes).

Synergistic effect:
The combination of two mechanisms in a single molecule provides a more powerful effect on blood glucose levels and body weight compared with drugs of the GLP-1–only class (for example, semaglutide, liraglutide).